profile image

Bruno Mäder

Head of the Biosimilar Business Unit, Merck Canada Inc.

Bruno Mäder is Head of the Biosimilar Business Unit at Merck Canada Inc. where he plays an active role in shaping global market access strategy as a member of the global Biosimilars team.

He has worked in the pharmaceutical industry for over 20 years, and prior to his current role, held the position of General Manager, OTC products for Merck Canada. He is also a former Chairman of OTC industry association Consumer Health Products Canada.

Bruno began his career at Schering Plough Canada in 1993. There, he created the Immunology division which he continued to lead at Merck after the two organizations merged in 2011. While at Schering, he also launched Remicade in Canada, leading the division during the launch of Simponi. During this period, he also led the opening of the first private infusion clinics for Remicade in Canada as well as the launch of the Bioadvance patient and physician support program.